Posts by Mourabit Halima

Professor Haiwen Huang from The First Affiliated Hospital of Soochow University provided an enlightening discourse on the significant strides made in CAR T cell therapies, with a special emphasis on their pioneering work in FcRH5 CAR-T cells for multiple myeloma. The study not only showcased the remarkable journey of hematology research over the years but also spotlighted the transformative potential of next-generation CAR T cell therapies in offering new hope to patients with hematologic cancers.

In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory marginal zone lymphoma are of paramount importance. It is in this context that the recent phase 2, multicenter, open-label study investigating the efficacy of Orelabrutinib comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Haiwen Huang from The First Affiliated Hospital of Soochow University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented in the American Journal of Hematology, underscoring not only the potential of Orelabrutinib as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at the renowned Beijing Hematologic Tumor and Immunology Summit Forum, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.

Immunotherapy has recently emerged as a focal area in the research of hematologic oncology. The advancement of genetic engineering and molecular biology, coupled with deeper insights into the mechanisms of cancer, has led to the widespread clinical adoption of Chimeric Antigen Receptor T Cell (CAR-T) therapy. This approach has demonstrated remarkable efficacy in treating refractory or relapsed acute lymphoblastic leukemia, aggressive lymphomas, and multiple myeloma, significantly improving patient outcomes. However, challenges persist, notably in patients who do not respond to treatment, relapse shortly, or experience severe adverse reactions like cytokine release syndrome. The pursuit to mitigate the side effects of CAR-T therapy and enhance its long-term clinical effectiveness is ongoing, filled with both challenges and opportunities.

 Diffuse large B-cell lymphoma (DLBCL) is a typical B-cell lymphoma, characterized by high invasiveness and heterogeneity. After standard first-line treatment, some patients still face relapse/refractory issues and relatively poor prognosis. Recently, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum" was successfully held in Beijing from March 1st to 3rd, 2024. After the conference, Oncology Frontier - Hematology Frontier specially invited Professor Jun Zhu from Peking University Cancer Hospital to share the unmet needs of DLBCL patients and their treatment strategies.

Thrombocytopenia is a common hematologic adverse reaction to cancer treatment, which can increase the risk of bleeding, prolong hospitalization, increase medical costs, and in severe cases, lead to death. Recently, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum", hosted by the Chinese Society of Immunology Hematology Branch and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology and Beijing Hospital of Peking University, was held successfully in Beijing from March 1st to 3rd, 2024. After the conference, Oncology Frontier - Hematology Frontier invited Professor Hu Zhou from Henan Cancer Hospital to share the diagnosis and treatment progress of tumor-related thrombocytopenia.

The "7th Beijing Thrombosis and Hemostasis Conference of the Chinese Society of Immunology Hematology Branch" and the "5th Beijing Hematologic Tumor and Immunology Summit Forum" sponsored by the Chinese Society of Immunology Hematology Branch and hosted by the National Clinical Research Center for Hematologic Diseases- Peking University Institute of Hematology and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was held in Beijing from March 1st to 3rd, 2024. During the conference, Oncology Frontier - Hematology Frontier had the honor to invite Professor Jun Ma from the Harbin Institute of Hematology and Oncology to share the development process of hematology in recent decades and advances in the treatment of hematologic tumors.

As spring arrives, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference focused comprehensively on hematopoietic stem cell transplantation, bringing together many renowned experts in the field of hematology from both domestic and international arenas. Centered around the basic and clinical research of hematopoietic stem cell transplantation, the conference covered various topics including advancements in transplantation indications, new transplantation models, prevention and treatment strategies for transplantation complications and relapse, progress in basic research, and transplantation-related clinical trials. During the conference, Oncology Frontier - Hematology Frontier had the honor to interview Professor Xiaohui Zhang from Peking University People's Hospital, who shared the significant progress made in the field of hematopoietic stem cell transplantation in China in recent years.

 Acute graft-versus-host disease (aGVHD) is a severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a major cause of non-relapse mortality in patients with hematologic malignancies. Although treatment options for aGVHD have advanced in recent years, the prognosis remains poor. Recently, the "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was held from March 1st to 3rd, 2024, in Beijing. Following the conference, Oncology Frontier - Hematology Frontier had the honor of inviting Professor Erjie Jiang, Director of the Stem Cell Transplantation Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science, to share insights on the challenges, risk factors, and diagnostic and therapeutic advances in acute graft-versus-host disease (aGVHD).

From March 1st to 2nd, 2024, the "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was grandly held in Beijing. Many renowned experts and scholars in the field of hematology gathered to share and exchange insights on topics such as the basics and clinical research of hematopoietic stem cell transplantation, advancements in transplantation indications, new transplantation modalities, prevention and treatment strategies for transplant complications and relapse, progress in basic research, and transplantation-related clinical trials. During the conference, Oncology Frontier - Hematology Frontier was honored to invite Professor Qifa Liu  from the Department of Hematology at Southern Medical University Nanfang Hospital to conduct in-depth discussions on topics such as "Clinical Research Design and Registration Standards" and standardization of hematologic tumor treatment. The following is a summary of the discussion.